N/A
Completed N=1,205
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
Source: ClinicalTrials.gov NCT04669366 ↗Enrolled (actual)
1,205
Serious AEs
—
Results posted
Jul 2024
Primary outcomePrimary: Number of Participants With at Least 1 Filled Sunitinib Prescription — 704; 320; 71; 53 Participants
Summary
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With at Least 1 Filled Sunitinib Prescription |
704; 320; 71; 53 | — |
| PRIMARY Number of Participants With 4:2 Sunitinib Schedule Without Any Modification |
704 | — |
| PRIMARY Number of Participants With 2:1 Sunitinib Schedule Without Any Modification |
320 | — |
| SECONDARY Number of Participants Switched From 4:2 Sunitinib Schedule to 2:1 Sunitinib Schedule |
71 | — |
| SECONDARY Number of Participants on Second Line Treatment With at Least 1 Filled Axitinib Prescription |
110 | — |
| SECONDARY Time to Treatment Discontinuation (TTD) |
4.55; 6.20; 13.91; 5.19 | — |
| SECONDARY Overall Survival (OS) |
13.48; 21.79; 32.20; 12.23 | — |
Eligibility Criteria
Inclusion Criteria
- all patients aged ≥ 18 years with at least one filled prescription of an oral targeted therapy relevant for treating mRCC registered in the Swedish Prescribed Drug Register (PDR) between July 1st 2005 and June 30th 2020. The Anatomical Therapeutic Chemical (ATC) codes for the oral drugs relevant for treating mRCC are the following: L01XE04 (sunitinib), L01XE05 (sorafenib), L01XE11 (pazopanib), L01XE17 (axitinib), L01XE10 (everolimus), L01XE26 (cabozantinib), L01XE34 (tivozantib), L01XE29 (lenvatinib).
- The patients identified in the PDR that also are identified in the SCR with the International Classification of Diseases and Related Health Problems (ICD)-7 diagnosis codes I800 or I809 and ICD-10 codes C64.0 and C64.9 from January 1st 2000 until December 31st 2019;excluding ICD-7 code I801 (cancer of the renal pelvis) will be included in the analysis set.
Exclusion Criteria
Patients with ICD-7 code I801 will be excluded
Data sourced from ClinicalTrials.gov (NCT04669366). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.